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Abstract  13 
A key feature of Shigella pathogenesis is the ability to spread from cell to cell post invasion. This 14 
is dependent on the bacteria's ability to initiate de novo F-actin tail polymerisation, followed by 15 
protrusion formation, uptake of bacteria-containing protrusion and finally lysis of the double 16 
membrane vacuole in the adjacent cell. In epithelial cells cytoskeletal tension is maintained by 17 
the actin-myosin II networks. In this study, the role of myosin II and its specific kinase, myosin 18 
light chain kinase (MLCK) during Shigella intercellular spreading was investigated in HeLa 19 
cells. Inhibition of MLCK and myosin II, as well as myosin IIA knockdown significantly 20 
reduced Shigella plaque and infectious focus formation. Protrusion formation and intracellular 21 
bacterial growth was not affected. Low levels of myosin II were localised to the Shigella F-actin 22 
tail. HeLa cells were also infected with Shigella strains defective in cell-to-cell spreading. 23 
Unexpectedly loss of myosin IIA labelling was observed in HeLa cells infected with these 24 
mutant strains. This phenomenon was not observed with WT Shigella or with the less abundant 25 
myosin IIB isoform, suggesting a critical role for myosin IIA. 26 
 27 
Introduction 28 
Shigella flexneri is the causative agent of bacillary dysentery (shigellosis). Post ingestion, 29 
Shigella bacteria invade the host intestinal epithelium via microfold cells. Resident macrophages 30 
in the follicle-associated epithelium undergo cell death (pyroptosis) induced by Shigella through 31 
caspase-1 activation, which releases interleukin-1β and interleukin-18 (Zychlinsky et al., 1992; 32 
Sansonetti et al., 2000; Senerovic et al., 2012). Interleukin-1β induces a strong inflammatory 33 
response and interleukin-18 magnifies innate immune responses (Sansonetti et al., 2000). After 34 
Shigella are released into the basolateral compartment, Shigella invade enterocytes via the type 35 
three secretion system, followed by lysis of the endocytic vacuole and replication in the host 36 
cytoplasm (Sansonetti et al., 1986; Cossart & Sansonetti, 2004). Concurrently the Shigella IcsA 37 
(VirG) protein interacts with the host Neural Wiskott-Aldrich syndrome protein (N-WASP) and 38 
Arp2/3 complex to initiate de novo F-actin nucleation and polymerisation, leading to actin-based 39 
motility (ABM) (Bernardini et al., 1989; Suzuki et al., 1998; Rohatgi et al., 1999).  40 
 41 
ABM facilitates Shigella intracellular movement and intercellular spreading into neighbouring 42 
cells via protrusion formation. After escaping from the double membrane vacuole, subsequent 43 
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cycles of infection are initiated (Schuch et al., 1999). Shigella ABM is dependent on IcsA, an 44 
outer membrane protein, and lipopolysaccharide (LPS) found on the bacterial surface (Makino et 45 
al., 1986; Bernardini et al., 1989; Lett et al., 1989). IcsA is necessary for pathogenesis as ∆icsA 46 
strains have attenuated virulence in human volunteers and in animal infection models (Makino et 47 
al., 1986; Kotloff et al., 1996; Sansonetti et al., 1999). Smooth (WT) Shigella strains express the 48 
complete LPS molecule, i.e. the lipid A core, core oligosaccharide and O-antigen subunit. In 49 
rough LPS strains the O-antigen subunit is absent due to mutations in chromosomal genes 50 
encoding LPS synthesis. Rough strains can invade epithelial cells and initiate ABM but have a 51 
defect in cell-to-cell spreading (Okamura et al., 1983; Hong & Payne, 1997; Van Den Bosch et 52 
al., 1997).  53 
 54 
Enterocytes, the site of Shigella infection, are polarised colonic epithelial cells characterised by 55 
apical junctional complexes, consisting of tight junctions and adherens junctions at the most 56 
apical end, which are undercoated with a prominent network of actin-myosin II (actomyosin) 57 
ring (Miyoshi & Takai, 2005). For cell-to-cell spreading to occur, the tensions of the actomyosin 58 
ring have to be overcome before disruption of the cellular contacts can take place (Rajabian et 59 
al., 2009). Shigella engulfment, but not protrusion formation into the neighbouring cell is 60 
triggered by phosphoinositide 3-kinase and is dependent upon dynamin II, Epsin-1 and clathrin, 61 
components of the clathrin-mediated endocytic pathway (Fukumatsu et al., 2012; Lum et al., 62 
2013). Adherens junction and tight junction components such as L-CAM, α-catenin, β-catenin, 63 
α-actinin and vinculin localise to the Shigella actin tail during protrusion formation. L-CAM is 64 
crucial for cell-to-cell spread as it helps to maintain a tight association between the bacterium 65 
and the membrane of the protrusions (Kadurugamuwa et al., 1991; Sansonetti et al., 1994). 66 
Knockdown of myosin-X, a component of adherens junctions, resulted in shortened and 67 
thickened protrusion stalks which reduced Shigella's ability to form plaques (Bishai et al., 2012). 68 
Shigella invasion and dissemination is also dependent on ATP release by connexin 26, and 69 
formins, Dia1 and Dia2 (Tran Van Nhieu et al., 2003; Heindl et al., 2009). Similar to the Arp2/3 70 
complex, formins initiate de novo actin polymerisation but also crosslink actin filaments (Esue et 71 




In an attempt to identify host proteins which are differentially recruited to rough and smooth LPS 74 
Shigella strains, localisation of various proteins to the F-actin tail and bacterial cells inside 75 
infected HeLa cells were carried out by immunofluorescence (IF) microscopy with a panel of 76 
antibodies. Curiously it was observed that non-muscle myosin IIA (myosin IIA), but not IIB 77 
protein levels were significantly reduced in HeLa cells infected with rough LPS (R-LPS) and 78 
∆icsA strains. The involvement of myosin and its specific kinase, myosin light chain kinase 79 
(MLCK) has previously been reported at different stages of Shigella infection. MLCK and 80 
myosin II were previously implicated in Shigella cell-to-cell spread in Caco-2 cells (Rathman et 81 
al., 2000). In a later study Mostowy et al. (2010) showed that in HeLa cells, myosin II was 82 
recruited to the septin cage which entraps intracytosolic Shigella without F-actin tails and targets 83 
the bacterium to the autophagy pathway for degradation. 84 
 85 
In this study, treatment of HeLa cells with MLCK and myosin II inhibitors, as well as siRNA 86 
knockdown of myosin IIA heavy chain (MYH9) reduced Shigella infectious focus and plaque 87 
formation. No effect on intracellular bacterial growth and bacteria protrusion formation were 88 
observed. Low levels of myosin IIA were also localised to the Shigella F-actin tail. Indirect 89 
protein quantification with fluorescence labelling showed that myosin IIA, but not IIB protein 90 
levels decreased by ~50% in a subpopulation of HeLa cells infected with ∆icsA and R-LPS 91 
Shigella strains which are defective in cell-to-cell spreading. Furthermore a significantly greater 92 
proportion of HeLa cells infected with the Shigella ∆icsA, R-LPS double mutant had reduced 93 
myosin IIA compared to ∆icsA or R-LPS-infected HeLa cells, suggesting a synergistic effect 94 
between the IcsA and LPS defects.  95 
 96 
Materials and methods 97 
Bacterial strains and growth media  98 
The strains used in this study are listed in Table 1. S. flexneri strains were grown from a Congo 99 
Red positive colony as described previously (Morona et al., 2003) and were routinely cultured in 100 
Luria Bertani (LB) broth and on LB agar. Bacteria were grown in media for 16 h with aeration, 101 
subcultured 1/20 and then grown to mid-exponential growth phase by incubation with aeration 102 
for 1.5 h at 37°C. Where appropriate, media were supplemented with tetracycline (4 or 10 μg 103 
mL
-1




Chemicals and antibodies  106 
(-)-Blebbistatin (50 mM stock - 203391; Merck Calbiochem), (+)-blebbistatin (50 mM stock - 107 
203392; Merck Calbiochem), ML-7 (30 mM stock - I2764; Sigma-Aldrich) and ML-9 (100 mM 108 
stock - C1172; Sigma-Aldrich) were prepared in dimethyl sulfoxide (DMSO) (D2650; Sigma-109 
Aldrich). Rabbit anti-Myosin IIA (M8064; Sigma-Aldrich) and rabbit anti-GAPDH antibodies 110 
(600-401-A33; Rockland Immunochemicals, Inc.) were used at 1:400 and 1:3000 for Western 111 
immunoblotting, respectively. For immunofluorescence (IF) microscopy, rabbit anti-Myosin IIA, 112 
rabbit anti-Myosin IIB (M7939; Sigma-Aldrich) and Alexa 594-conjugated donkey anti-rabbit 113 
secondary antibodies (Molecular Probes) were used at 1:100.  114 
 115 
Reverse transfection and HeLa cell lysate preparation  116 
MYH9 (Myosin IIA) siRNA (L-007668-00-0005) and siRNA controls (Non-targeting Pool; D-117 
001810-10-05, siGLO Green Transfection Indicator; D-001630-01-05) were purchased from 118 
Thermo Scientific. siRNAs were transfected with DharmaFECT 3 Transfection Reagent (T-119 
2003-03) and DharmaFECT Cell Culture Reagent (DCCR; B-004500-100), also purchased from 120 
Thermo Scientific. Reverse transfection of HeLa cells (Human, cervical, epithelial cells ATCC 121 
#CCL-70) were carried out based on a method by Thermo Scientific. siRNA were prepared as a 122 
5 µM stock and the final concentration used was 50 nM. HeLa cells were transfected and HeLa 123 
cell lysate were prepared as described previously (Lum et al., 2013). 124 
  125 
SDS-PAGE and Western immunoblotting  126 
SDS-PAGE (12% acrylamide gel) and Western immunoblotting were carried out as described 127 
previously (Lum et al., 2013). Molecular weight markers used were BenchMark™ Pre-Stained 128 
Protein Ladder (Invitrogen). 129 
 130 
Plaque assay  131 
Plaque assays were performed with HeLa cells as described previously (Oaks et al., 1985) with 132 
modifications. 1.2 × 10
6
 HeLa cells were seeded in six-well trays in minimal essential medium 133 
(MEM), 10% FCS, 1% penicillin/streptomycin. Cells were grown to confluence overnight and 134 





 mid-exponential phase bacteria were added to each well. Trays were incubated at 37°C, 5% 136 
CO2 and were rocked gently every 15 min to spread the inoculum evenly across the well. At 90 137 
min post infection, the inoculum was aspirated. 3 mL of the first overlay (DMEM, 5% FCS, 20 138 
µg mL
-1
 gentamicin, 0.5% (w/v) agarose [Seakem ME]) was added to each well. ML-7, ML-9 or 139 
DMSO were added and were swirled to ensure even distribution. The second overlay (DMEM, 140 
5% FCS, 20 µg mL
-1
 gentamicin, 0.5% (w/v) agarose, 0.1% (w/v) Neutral Red solution [Gibco 141 
BRL]) was added 48 h post infection and plaques were imaged 6 h later. All observable plaques 142 
were counted and the diameter was measured for each condition in each experiment. At least 50 143 
plaques were measured for each condition. 144 
 145 
Infectious focus assay  146 
1.2 × 10
6
 HeLa cells were seeded in six-well trays in MEM, 10% FCS, 1% 147 
penicillin/streptomycin. Cells were grown to confluence overnight and were washed twice with 148 
DMEM prior to inoculation. 5 × 10
4
 mid-exponential phase bacteria expressing mCherry were 149 
added to each well. Trays were incubated at 37°C, 5% CO2 and were rocked every 15 min to 150 
spread the inoculum evenly across the well. At 90 min post infection, the inoculum was 151 
aspirated. 1.5 mL of DMEM (phenol red-free) (31053-028; Life Technologies), 1 mM sodium 152 
pyruvate, 5% FCS, 20 µg mL
-1
 gentamicin, 2 mM IPTG was added to each well. (+)-153 
Blebbistatin, (-)-blebbistatin or DMSO were added and were swirled to ensure even distribution. 154 
24 h later the infectious foci were imaged with an Olympus IX-70 microscope using a 10× 155 
objective. The filter set used was DA/FI/TX-3X-A-OMF (Semrock). Fluorescence and phase 156 
contrast images were captured and false colour merged with the Metamorph software program 157 
(Version 7.7.3.0, Molecular Devices). The area of the infectious focus, i.e. area where mCherry 158 
was expressed, was outlined and measured with Metamorph. All observable infectious foci were 159 
counted and the area was measured for each condition in each experiment. At least 15 infectious 160 
foci were measured for each condition. The following modifications were made for transfected 161 
cells. HeLa cells were transfected prior to infectious focus assay as described previously in 12-162 
well trays (Lum et al., 2013). On day 3, the infectious focus assay was carried out. Transfected 163 
HeLa cells were washed twice with DMEM prior to inoculation. 5 × 10
4
 mid-exponential phase 164 




Invasion assay and immunofluorescence (IF) microscopy  167 
HeLa cells (8 × 10
4
) were seeded onto sterile glass cover slips in 24-well trays in MEM, 10% 168 
FCS, 1% penicillin/streptomycin. For transfected cells, HeLa cells were transfected as described 169 
previously (Lum et al., 2013). Cells were grown to semi-confluence overnight, washed twice 170 
with Dulbecco’s PBS (D-PBS) and once with MEM, 10% FCS. 4 × 107 mid-exponential phase 171 
bacteria were added to each well and subsequently centrifuged (2,000 rpm, 7 min, Heraeus 172 
Labofuge 400 R) onto HeLa cells. After 1 h incubation at 37°C, 5% CO2, the infected cells were 173 
washed thrice with D-PBS and incubated with 0.5 mL MEM containing 40 µg mL
-1
 gentamicin 174 
for a further 1.5 h (or 3.5 h for labelling with anti-activated caspase 3). Infected cells were 175 
washed thrice in D-PBS, fixed in 3.7% (v/v) formalin for 15 min, incubated with 50 mM NH4Cl 176 
in D-PBS for 10 min, followed by permeabilisation with 0.1% Triton X-100 (v/v) for 5 min. 177 
After blocking in 10% FCS in PBS, the infected cells were incubated at 37°C for 30 min with the 178 
desired primary antibody. After washing in PBS, coverslips were incubated with Alexa 594-179 
conjugated donkey anti-rabbit secondary antibody (Molecular Probes) (1:100). F-actin was 180 
visualised by staining with Alexa Fluor 488-conjugated phalloidin (2 U mL
-1) and 4’,6’-181 
diamidino-2-phenylindole (DAPI) (10 μg mL-1) was used to counterstain bacteria and HeLa cell 182 
nuclei. Coverslips were mounted on glass slides with Mowiol 4-88 (Calbiochem) containing 1 183 
µg mL
-1 
p-phenylenediamine (Sigma) and was imaged using a 100× oil immersion objective 184 
(Olympus IX-70). The filter set used was DA/FI/TX-3X-A-OMF (Semrock). Fluorescence and 185 
phase contrast images were false colour merged using the Metamorph software program.  186 
 187 
Indirect quantification of protein levels by IF 188 
Indirect immunofluorescence was quantified with Metamorph to determine protein levels in 189 
bacteria-infected HeLa cells compared to uninfected HeLa cells. "Invasion assay and IF 190 
microscopy" was carried out as described above. Cells were imaged with a 40× objective. In 191 
each image, the maximum fluorescence (100%) was determined by the mean fluorescence of 192 
uninfected HeLa cells (2 - 3 cells). Infected and uninfected cells were selected by tracing and the 193 
mean fluorescence of the outlined area was determined with Metamorph. HeLa cells exhibited 194 
two distinct immunofluorescence staining patterns (high and low) when infected compared to 195 
uninfected HeLa cells. In such instances, the HeLa cells were arbitrarily assigned into distinct 196 
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populations, before the level of fluorescence of the infected cell was determined. The 197 
fluorescence of ≥ 100 infected cells for each category was measured for each experiment.  198 
 199 
Protrusion formation  200 
HeLa cells were seeded, infected and fixed as per "Invasion assay and IF microscopy". HeLa 201 
cells were washed twice with 1× Annexin V binding buffer (99902; Biotium) prepared in milliQ 202 
(18.2 MΩ·cm) water, mounted on glass slides with the same buffer and were imaged using a 40× 203 
oil immersion phase contrast objective (Olympus IX-70). Protrusion formation was defined as 204 
any extensions of bacterial projection(s) (minimum of a full bacterial length) beyond the 205 
periphery of the HeLa cell. For each condition in each experiment, a minimum of 100 cells were 206 
imaged. 207 
 208 
Assay for growth of intracellular bacteria  209 
HeLa cells (8 × 10
4
) were seeded in 24-well trays in MEM, 10% FCS, 1% 210 
penicillin/streptomycin. Cells were grown to semi-confluence overnight, washed twice with D-211 
PBS and once with MEM, 10% FCS. 4 × 10
7
 mid-exponential phase bacteria were added to each 212 
well (multiplicity of infection ~500). The bacteria were centrifuged (2,000 rpm, 7 min, Heraeus 213 
Labofuge 400 R) onto HeLa cells. After 1 h incubation at 37°C, 5% CO2, the infected cells were 214 
washed thrice with D-PBS and incubated with 0.5 mL MEM containing 40 µg mL
-1 
of 215 
gentamicin. At the indicated intervals, monolayers (in duplicate) were washed four times in D-216 
PBS and were lysed with 0.1% (v/v) Triton X-100 in PBS for 5 min and bacteria were 217 
enumerated on tryptic soy agar (Gibco) plates.  218 
 219 
Statistical analysis  220 
Statistical analysis was carried out using GraphPad Prism 6. Results are expressed as means ± 221 
SEM of data obtained in independent experiments. Statistical differences between three or more 222 
groups were determined with a one-way ANOVA followed by Tukey's or Dunnett's multi 223 
comparison post hoc test. Statistical significance was set at p < 0.05.  224 
 225 
Results  226 
MLCK and myosin IIA are essential for S. flexneri cell-to-cell spreading in HeLa cells 227 
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Preliminary data from our laboratory suggested that HeLa cells infected with Shigella strains 228 
defective in cell-to-cell spreading (∆icsA and R-LPS) strains have significantly reduced myosin 229 
IIA, but not IIB protein levels. Hence the study is focused on myosin IIA. ML-7 and ML-9 230 
inhibit the catalytic activity of MLCK by out competing ATP binding, however ML-9 is more 231 
potent compared with ML-7 (Saitoh et al., 1987). HeLa monolayers infected with S. flexneri 232 
were treated with increasing concentrations of ML-7 or ML-9 or with the DMSO vehicle alone 233 
(Fig. 1). ML-7 and ML-9 treatment reduced Shigella plaque size (Fig. 1A, C and E), but not 234 
plaque numbers (Fig. 1B and 1D). Treatment with 50 μM ML-9 abolished plaque formation 235 
altogether (Fig. 1D).  236 
 237 
Blebbistatin exists in two (±) enantiomeric forms. The active (-) enantiomer (Straight et al., 238 
2003) preferentially binds the myosin II active site when ATP has been hydrolysed to the 239 
intermediate ADP and phosphate, hence slowing down phosphate release. Blebbistatin binding 240 
also locks myosin II in a state which reduces actin binding (Kovacs et al., 2004; Ramamurthy et 241 
al., 2004). HeLa monolayers infected with S. flexneri were treated with increasing concentrations 242 
of (+)-blebbistatin, (-)-blebbistatin or with the DMSO vehicle alone (Fig. 2A - C). Infectious foci 243 
formation was abolished when HeLa cells were treated with 50 μM (-)-blebbistatin (Fig. 2B). No 244 
effect on infectious foci formation was observed with the inactive (+)-enantiomer, as expected 245 
(Fig. 2A - C).  246 
 247 
To examine the effect of myosin IIA depletion on S. flexneri cell-to-cell spreading, HeLa cells 248 
were transfected with myosin IIA (MYH9) siRNA and an infectious focus assay was carried out. 249 
Western immunoblots of HeLa cells lysates two days post siRNA treatment showed ~80% 250 
reduction in myosin IIA levels (Fig. 2D). S. flexneri formed infectious foci on HeLa cells treated 251 
with myosin IIA siRNA with a reduced mean focus area (***p < 0.001) (Fig. 2E and G) but not 252 
foci counts (Fig. 2F) when compared with HeLa cells treated with the negative control siRNA. 253 
Therefore myosin II inhibition with (-)-blebbistatin as well as myosin IIA siRNA knockdown 254 
reduced Shigella cell-to-cell spreading. Inhibition of MLCK with ML-7 and ML-9 also 255 




MLCK and myosin II inhibitors do not affect bacterial replication and protrusion 258 
formation 259 
The inability of S. flexneri to form plaques can be attributed to reduced bacterial replication or 260 
inability to mediate protrusion formation. Semi-confluent HeLa cells were initially infected with 261 
S. flexneri to allow bacterial invasion into HeLa cells before treatment with ML-7, ML-9 and (-)- 262 
blebbistatin. The number of intracellular bacteria was calculated at 1, 2, 4 and 6 h post 263 
incubation in gentamicin, which kills extracellular bacteria. As shown in Fig. 3A, HeLa cells 264 
treated with DMSO or MLCK or myosin II inhibitors had no adverse effect on the rate of 265 
intracellular replication.  266 
 267 
Bacterial protrusion formation was also determined in HeLa cells treated with MLCK and 268 
myosin inhibitors. Semi-confluent HeLa cells were initially infected with S. flexneri to allow 269 
bacterial invasion into HeLa cells before treatment with ML-7, ML-9 and (-)-blebbistatin for 1.5 270 
h. HeLa cells treated with DMSO or MLCK or myosin II inhibitors formed protrusions similar to 271 
untreated HeLa cells (Fig. 3C). No differences in % infected HeLa cells with bacterial protrusion 272 
were observed (Fig. 3B).  273 
 274 
Myosin IIA is localised to the S. flexneri F-actin tail  275 
The S. flexneri IcsA protein is localised at the old pole of the bacteria and interacts with the host 276 
N-WASP, which in turn recruits the Arp2/3 complex to initiate actin polymerisation. The F-actin 277 
tail that is formed imparts motility to the bacteria (Goldberg et al., 1993; Suzuki et al., 1998; 278 
Goldberg, 2001). The localisation of myosin IIA in S. flexneri-infected HeLa cells was 279 
investigated with IF microscopy. In untreated HeLa cells, myosin IIA is localised at the 280 
cytoplasm, cortex and stress fibers, and co-localises with the S. flexneri F-actin tail (Fig. 4A). 281 
This was similarly observed when HeLa cells were treated with DMSO and infected with S. 282 
flexneri (Fig. 4B). Treatment of infected HeLa cells with MLCK inhibitors, ML-7 and ML-9, did 283 
not affect myosin IIA localisation to bacterial F-actin tail (Fig. 4C and D). 284 
 285 
HeLa cells were also treated with the myosin II inhibitor, blebbistatin. As expected treatment 286 
with the inactive (+) enantiomer did not affect myosin II localisation to the bacteria F-actin tail 287 
(Fig. 4E). Treatment with (-)-blebbistatin resulted in loss of stress fibres integrity and 288 
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exaggerated membrane ruffling (Fig. 4F). In myosin IIA siRNA-transfected cells, a reduction in 289 
cellular myosin IIA protein levels was observed, as expected (Fig 4G). Myosin II inhibition with 290 
(-)-blebbistatin and siRNA knockdown did not affect S. flexneri F-actin tail formation nor 291 
myosin IIA localisation to F-actin tail (Fig. 4F and G). The frequency of S. flexneri comet tail 292 
formation also did not differ between untreated cells, MYH9 siRNA-transfected cells and cells 293 
treated with DMSO, ML-7, ML-9 or both enantiomers of blebbistatin (data not shown). Hence F-294 
actin tail formation is not dependent on either MLCK or myosin IIA.  295 
 296 
Two distinct myosin IIA staining patterns are observed in HeLa cells infected with S. 297 
flexneri R-LPS and ∆icsA strains 298 
IcsA and LPS are important for S. flexneri cell-to-cell spreading. In R-LPS strains, IcsA polar 299 
localisation and ABM is affected, but bacteria can still invade cells (Sandlin et al., 1995; Van 300 
Den Bosch et al., 1997). R-LPS strains also form F-actin tails, albeit infrequently and are 301 
shortened and distorted (Van Den Bosch et al., 1997). S. flexneri ∆icsA strains can invade cells 302 
but do not form F-actin tails and hence are defective in cell-to-cell spreading (Goldberg & 303 
Theriot, 1995; Van Den Bosch & Morona, 2003). The localisation of myosin IIA in HeLa cells 304 
infected with ∆icsA and R-LPS strains was investigated with IF microscopy. While myosin IIA 305 
was observed in infected HeLa cells, the level of staining observed varied greatly between WT S. 306 
flexneri, R-LPS, ∆icsA or ∆icsA, R-LPS-infected HeLa cells (Fig. 5A). 307 
 308 
The relative myosin IIA fluorescence of infected HeLa cells was quantified by comparing 309 
myosin IIA staining intensity in infected HeLa cells relative to the mean staining intensity of two 310 
to three uninfected HeLa cells within the same image. The maximum intensity of uninfected 311 
HeLa cells was set at 100% (Fig. 5E). In HeLa cells infected with WT S. flexneri 2457T, myosin 312 
IIA staining did not differ from uninfected HeLa cells (90.59 ± 6.79 %) (Fig. 5A and E). HeLa 313 
cells infected with S. flexneri R-LPS (RMA723) had more intracellular bacteria in the cytoplasm 314 
(Fig. 5B - column 1) compared to the WT strain (Fig. 5A - column 1), presumably due to 315 
intercellular spreading defects. As seen in Fig. 5B (column 2), two different myosin IIA staining 316 
was observed. Infected HeLa cells either had similar myosin IIA protein levels compared to the 317 
WT 2475T infected-HeLa cells or had uniform loss of myosin IIA from the cytoplasm, cortex 318 
and stress fibers. These cells were marked with ‡. The myosin IIA fluorescence of the two 319 
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distinct cell populations [RMA723 and RMA723 (Lo - low myosin IIA protein levels)] was 320 
measured from 200 cells from two independent experiments and differed significantly (89.69 ± 321 
3.97% vs 47.00 ± 1.43%, ***p < 0.001). The overall percentage of RMA723-infected cells with 322 
low myosin II protein levels was 25.30 ± 0.44% (Fig. 5F).  323 
 324 
Significant bacterial clumping was observed in HeLa cells infected with S. flexneri ∆icsA strain 325 
(Fig. 5C - column 1) compared to HeLa cells infected with the R-LPS strain (Fig. 5B, column 1). 326 
Individual bacterium could not be distinguished due to the overcrowding of bacteria in the HeLa 327 
cell cytoplasm (Fig. 5C - column 1). This was expected since ∆icsA mutants are deficient in cell-328 
to-cell spreading and are unable to spread laterally(delete). Similar to HeLa cells infected with 329 
the S. flexneri R-LPS strain, two distinct myosin IIA staining profiles were observed in HeLa 330 
cells infected with the ∆icsA strain (Fig. 5C - column 2). Infected HeLa cells with low myosin 331 
IIA staining were similarly marked with ‡ [RMA2041 (Lo)] and the mean myosin IIA intensity 332 
of this infected HeLa population was 54.43 ± 1.18%, which was significantly lower than 333 
RMA2041-infected HeLa cells with unaffected myosin IIA protein levels (91.36 ± 6.93%, **p < 334 
0.001). The overall percentage of RMA2041 (∆icsA)-infected cells with low myosin II protein 335 
levels was 30.31 ± 0.72%, which was not significantly different from that of RMA723 (R-LPS)-336 
infected cells (Fig. 5F). 337 
 338 
HeLa cells were infected with S. flexneri ∆icsA, R-LPS double mutant (RMA2043) to investigate 339 
if there were any synergistic effect between the ∆icsA and R-LPS mutants (Fig. 5D). Similar to 340 
HeLa cells infected with the ∆icsA strain (Fig. 5C - column 1), individual bacterium could not be 341 
distinguished due to significant bacterial clumping in the HeLa cytosol (Fig. 5D - column 1). 342 
Two distinct myosin IIA staining profiles were also observed in RMA2043-infected HeLa cells 343 
(Fig. 5D - column 2), similar to the R-LPS and ∆icsA mutants (Fig. 5B and C, column 2). The 344 
difference in mean myosin IIA labelling intensity between RMA2043-infected HeLa cells with 345 
no loss of myosin IIA staining and infected HeLa cells with significant reduction in myosin IIA 346 
protein levels [RMA2043 (Lo)] was 82.27 ± 0.14% and 49.25 ± 0.14% (**p < 0.001), 347 
respectively. Hence, no further reduction in myosin IIA protein levels was observed when both 348 
IcsA and LPS were mutated. No differences in F-actin cytoskeletal staining were observed 349 
between infected HeLa cells with typical or reduced myosin IIA protein levels (Fig. 5D, column 350 
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3). The overall percentage of RMA2043 (∆icsA, R-LPS)-infected cells with low myosin II 351 
protein levels was 43.97 ± 4.11%, which was higher (*p < 0.05) than RMA723 (R-LPS) and 352 
RMA2041 (∆icsA)-infected cells (Fig. 5F). The increased frequency of infected HeLa cells with 353 
reduced myosin IIA staining in the double mutant suggests the mutations had a synergistic effect.  354 
 355 
It is unclear how and why myosin IIA protein levels are decreased when infected with S. flexneri 356 
mutants defective in cell-to-cell spreading. The number of S. flexneri bacteria within the infected 357 
HeLa cell does not appear to be the distinguishing difference as bacterial loads appears to be 358 
similar between the two cell populations in either S. flexneri R-LPS, ∆icsA or ∆icsA, R-LPS-359 
infected HeLa cells (Fig. 5B - D, column 1). Furthermore no changes to the cell shape or actin 360 
cytoskeleton is observed in spite of the reduced myosin IIA protein levels (Fig. 5B - D, column 361 
3). The HeLa cell line used in this study also expresses myosin IIB (Betapudi, 2010). Myosin IIB 362 
localisation in HeLa cells during S. flexneri infection was investigated by IF microscopy (Fig. 6). 363 
Myosin IIB staining was similar to myosin IIA, but is more pronounced at the stress fibres. HeLa 364 
cells were infected with S. flexneri 2457T (WT), RMA723 (R-LPS), RMA2041 (∆icsA) or 365 
RMA2043 (∆icsA, R-LPS) and myosin IIB localisation was examined (Fig. 6). Similar levels of 366 
myosin IIB staining were observed in both infected and uninfected HeLa cells. It appears the 367 
distinctive myosin II staining in S. flexneri R-LPS or ∆icsA-infected HeLa cells is specific for 368 
isoform IIA. 369 
 370 
Discussion 371 
In an attempt to differentiate host proteins which are recruited to rough and smooth Shigella 372 
strains, we observed that myosin IIA but not IIB protein levels were significantly reduced in 373 
HeLa cells infected with R-LPS and ∆icsA strains. Previously inhibition of myosin II and its 374 
specific kinase, MLCK, reportedly reduced the size of Shigella foci of infection in Caco-2 cells 375 
(Rathman et al., 2000). In a separate study, Mostowy et al. (2010) showed that in HeLa cells, 376 
myosin II was recruited to the septin cage which entraps intracytosolic Shigella without F-actin 377 
tails and targets the bacterium to the autophagy pathway for degradation. In this study the 378 
contribution of myosin IIA and MLCK during Shigella cell-to-cell spreading in HeLa cells was 379 
investigated with inhibitors and siRNA knockdown. The differences between myosin IIA and 380 




Shigella intercellular spreading in host cells is dependent on its ability to initiate de novo F-actin 383 
tail polymerisation, protrusion formation into neighbouring cells, engulfment of protrusions and 384 
lysis of the double membrane vacuole, and is dependent on both Shigella and host proteins. In 385 
eukaryotic cells, the cortical tension is maintain by the actin-myosin II (actomyosin) network 386 
(Pasternak et al., 1989) which is important for various processes such as lamellipodia formation 387 
(Betapudi, 2010) and maintaining cell morphology (Eliott et al., 1993; Wei & Adelstein, 2000; 388 
Even-Ram et al., 2007). Phosphorylation of myosin II regulatory light chain by a number of 389 
kinases, including MLCK and Rho-activated kinase activate myosin II ATPase activity, filament 390 
formation and contractile activity in vitro and in vivo (Conti et al., 2008; Conti & Adelstein, 391 
2008). Mammalian cells express three myosin II isoforms, IIA, IIB and IIC; however, in spite 392 
high degree of similarity in sequence identity and structural conservation, myosin II isoforms 393 
differ in enzymatic properties and subcellular localisation (Maupin et al., 1994; Conti et al., 394 
2008). The isoforms also have distinct and redundant roles depending on the specific cellular 395 
processes (Kelley et al., 1996; Kolega, 1998; Betapudi, 2010; Wang et al., 2011).  396 
 397 
Inhibition of MLCK and myosin II catalytic activity with ML-7, ML-9 and (-)-blebbistatin 398 
significantly reduced Shigella intercellular spreading. Knockdown of myosin IIA with siRNA 399 
similarly affected Shigella cell-to-cell spreading. Myosin IIA knockdown was not complete as 400 
low levels of the protein was detected with Western immunoblotting. Nonetheless myosin IIA 401 
inhibition reduced Shigella infectious focus area by > 60%. These results also suggest myosin 402 
IIB is unable to rescue myosin IIA function and that myosin IIA's role in Shigella cell-to-cell 403 
spreading is specific. These results are in agreement with previous findings that showed MLCK 404 
involvement during Shigella intercellular spreading in polarised Caco-2 cells (Rathman et al., 405 
2000). The authors also provided indirect evident for myosin II involvement (Rathman et al., 406 
2000). 407 
 408 
The inability to form plaques or infectious foci could be attributed to either reduced bacterial 409 
motility or lack of protrusion formation. Shigella F-actin tail formation occurred at a similar 410 
frequency to untreated cells. Furthermore Shigella protrusion formation in semi-confluent HeLa 411 
cells was also not significantly affected. This was in contrast to the previous report in confluent 412 
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Caco-2 cells where ML-7 inhibited Shigella protrusion formation as detected by transmission 413 
electron microscopy. In the few protrusions that were observed, Shigella bacteria was not tightly 414 
associated with the protruding membrane (Rathman et al., 2000). While that study primarily used 415 
Caco-2 cells, the authors also used semi-confluent HeLa cells to observe F-actin tail formation in 416 
the presence of ML-7. Both Shigella F-actin tail and protrusion formation were observed and 417 
were not significantly different from untreated, infected HeLa cells in that study, as we also 418 
observed (Rathman et al., 2000). No differences in Shigella viable cell counts were observed for 419 
ML-7, ML-9 and (-)-blebbistatin-treated HeLa cells, suggesting Shigella growth is unaffected. 420 
Hence the most likely explanation for reduced Shigella plaque or foci formation in the absence 421 
of MLCK and myosin II is likely due to a defect in the uptake of bacteria-containing protrusion 422 
into the neighbouring cells.  423 
 424 
In Mostowy et al. (2010)'s study, myosin II depletion with siRNA increased the number of 425 
Shigella-infected cells 4 h 40 min post-infection when observed with quantitative microscopy. 426 
Similar results were observed by flow cytometry when Caco-2 cells were treated with the myosin 427 
II inhibitor, blebbistatin (Mostowy et al., 2010). To rule out the possibility that myosin II 428 
inactivation increased Shigella cell-to-cell spread independently of septin caging, blebbistatin 429 
treatment was repeated with Listeria monocytogenes-infected Caco-2 cells (Mostowy et al., 430 
2010). Listeria also relies on F-actin tail formation for cell-to-cell spread (Gouin et al., 2005), 431 
but septin caging was not observed under similar experimental conditions (Mostowy et al., 432 
2010). Blebbistatin treatment did not increase, and even slightly reduced the number of Listeria-433 
infected Caco-2 cells and it was inferred loss of myosin II does not affect Shigella cell-to-cell 434 
spread and that inactivation of septin caging alone was responsible for the increase in Shigella 435 
intercellular spreading.  436 
 437 
The conclusion in reference to the role of myosin II and Shigella cell-to-cell spreading from 438 
Mostowy et al. (2010)'s study would appear contradictory to our findings and that of Rathman et 439 
al. (2000). The main issue with using Listeria as an alternative model is that myosin II and 440 
MLCK are not required for Listeria cell-to-cell spread regardless of septin caging. This has been 441 
demonstrated by various groups in Potorous tridactylis kidney (PtK2) cells (Cramer & 442 
Mitchison, 1995), Caco-2 cells (Rathman et al., 2000) and Caco-2 BBE1 cells (Rajabian et al., 443 
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2009). Hence the role of myosin II in Shigella intercellular spreading during septin caging of 444 
non-motile Shigella-infected HeLa cells requires further investigation. It is likely myosin II plays 445 
different roles during different stages of Shigella infection. Myosin II interaction with septin 446 
initially helps to target a subset of non-motile Shigella for destruction via autophagy. Shigella 447 
bacteria which have successfully initiated F-actin tail undergo replication and subsequently form 448 
protrusions into the neighbouring cells, whereby myosin II facilitates uptake of the bacterium. 449 
Depending on the experimental conditions, myosin II inhibition would result in different 450 
outcomes. In Mostowy et al. (2010)'s study, the number of infected cells were determined out 4 h 451 
40 min post infection whereas plaque and infectious focus formation are typically measured 24 - 452 
48 h post infection. 453 
 454 
 The Shigella IcsA outer membrane protein is localised to the old pole, ie the pole which exists 455 
prior to cellular division which gives rise to new daughter poles (Goldberg et al., 1993). IcsA 456 
polar localisation is also dependent on LPS. Shortening of LPS O-antigen chain length has 457 
revealed IcsA expression on the lateral surface of Shigella (Morona & Van Den Bosch, 2003). 458 
Hence LPS may act to mask IcsA on the lateral regions to reinforce polar localisation. 459 
Alterations of LPS O-antigen chain length also affect ABM and Shigella plaque formation 460 
adversely (Morona et al., 2003). In infected HeLa cells, myosin IIA and IIB were found at 461 
Shigella F-actin tail. However only myosin IIA protein levels in HeLa cells were significantly 462 
reduced (~50%) when infected with Shigella ∆icsA and R-LPS strains. This was observed in ~25 463 
- 30% of infected cells. No further decrease in myosin IIA labelling was observed when cells 464 
were infected with the ∆icsA, R-LPS double mutant, although the proportion of cells with 465 
reduced myosin IIA was almost doubled. This suggests that there might be some synergistic 466 
effects between ∆icsA and R-LPS mutations, although it is unclear how this interaction may 467 
occur. Shigella ∆icsA and R-LPS strains are defective in cell-to-cell spreading and over time, 468 
bacterial clumps accumulate within the HeLa cell cytoplasm. The uniform loss of myosin IIA 469 
could be partly attributed to the increased bacterial loads in HeLa cells. However infected cells 470 
with similar bacterial numbers can have either similar or decreased myosin IIA protein levels 471 
compared to uninfected neighbouring HeLa cells (Fig. 5). Nonetheless the increased bacterial 472 
load in the cytoplasm may trigger activation of an undefined signalling pathway which in turn 473 




In addition to its role in Shigella cell-to-cell spreading, recent studies implicate myosin II in the 476 
pathogenesis of several important bacterial pathogens such as Chlamydia, Salmonella 477 
Helicobacter. In Chlamydia, myosin IIA and IIB are required for extrusion egress following 478 
chlamydial development within a vacuole in the host. In the absence of myosin IIA and IIB 479 
activation, lytic egress is favoured (Lutter et al., 2013). The balance between lytic and extrusion 480 
egress mechanism is achieved in response to cellular signalling pathways and external 481 
environmental stimuli (Lutter et al., 2013). In Salmonella, the bacterial SopB protein mediates 482 
myosin IIA-dependent contractility, forming stress-fibre like structures which is thought to 483 
facilitate Salmonella entry into the host cell (Hänisch et al., 2011). Additionally myosin IIB 484 
induces cytoskeletal rearrangements around the Salmonella-containing vacuole (SCV) in the host 485 
cell, which may act to restrain bacterial growth and regulate bacterial virulence (Odendall et al., 486 
2012). Myosin IIA has also been reported to facilitate positioning of the SCV at the host nucleus 487 
(Wasylnka et al., 2008). In Helicobacter, increased myosin II activity resulted in subsequent loss 488 
of gastric mucosal tight junction barrier integrity which may contribute to the predisposition of 489 
gastric cancer development of (remove) (Posselt et al., 2013). In non-polarised gastric epithelial 490 
cells, inhibition of myosin II activity affected the rear retraction of the cell resulting in 491 
significantly altered cell shape (Lu et al., 2009), which may contribute to gastric carcinoma 492 
invasion and metastasis (Argent et al., 2004; Azuma et al., 2004; Basso et al., 2008). Hence 493 
myosin IIA and IIB play diverse roles during pathogenesis of different intracellular pathogens, 494 
which is distinct from its role in Shigella intercellular spread. In some cases, only one of the 495 
myosin II isoform is required suggesting myosin II specificity. 496 
 497 
Although we initially set out to identify host proteins which are differentially localised to 498 
Shigella smooth and rough strains, it was unexpectedly observed that Shigella strains defective in 499 
cell-to-cell spreading had reduced myosin IIA, but not IIB protein levels in a proportion of 500 
infected HeLa cells, suggesting specificity between the two isoforms. This was not surprising 501 
since myosin II isoforms have been reported to play different roles within the same cell type 502 
(Maupin et al., 1994; Betapudi, 2010). Furthermore different myosin II isoforms are also 503 




We also show that MLCK and myosin IIA inhibition significantly affected Shigella plaque 506 
formation but no effect on intracellular growth and protrusion formation was observed. Low 507 
levels of myosin IIA was detected in the Shigella F-actin tails. We hypothesize that the reduced 508 
plaque formation could be a defect in the uptake of bacteria-containing protrusion in the 509 
neighbouring cells. Previously components of the clathrin mediated endocytic pathway including 510 
dynamin, clathrin and Epsin-1 was shown to mediate bacterial uptake in the neighbouring cells 511 
(Fukumatsu et al., 2012; Lum et al., 2013). It is possible myosin IIA may interact with 512 
components of the endocytic pathway to facilitate uptake of bacteria-containing protrusions. 513 
Perhaps the loss of icsA or LPS O-antigen affected Shigella cell-to-cell spreading which led to 514 
downstream effects including bacterial overcrowding of HeLa cell cytoplasm, which in turn 515 
affected myosin IIA expression.  516 
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Table 1. Bacterial strains 673 
Strain Relevant characteristics
#
 Reference or source 
S. flexneri   
2457T S. flexneri 2a wild type Laboratory collection 
MLRM107 2457T [pMP7604; Tc
R
] (Lum et al., 2013) 
RMA723 2457T ΔrmlD::KmR (Van Den Bosch et al., 1997) 
RMA2041 2457T ΔicsA::TcR (Van Den Bosch & Morona, 2003) 
RMA2043 RMA2041 ΔrmlD::KmR (Van Den Bosch & Morona, 2003) 
# Tc
R
, Tetracycline resistant; Km
R
, Kanamycin resistant 674 





Fig. 1 MLCK inhibition reduces S. flexneri 2457T plaque size. HeLa cells were infected with 678 
S. flexneri 2457T in a plaque assay using a 6-well tray as described in the Methods. Plaque 679 
formation was performed in the presence of increasing concentrations of ML-7, ML-9 or the 680 
vehicle, 0.1 % DMSO. (A) Wells were stained with Neutral Red to makes plaques more visible. 681 
Scale bar = 2 mm. (B) The total plaque counts or (C) mean plaque diameters from each well 682 
treated with ML-7 and infected with Shigella were calculated. (D) The total plaque counts or (E) 683 
mean plaque diameters from each well treated with ML-9 and infected with Shigella were 684 
calculated. Data are represented as mean ± SEM of independent experiments (n = 3), analysed 685 
with one-way ANOVA (p < 0.0001 for ML-7 plaque counts and mean plaque diameters, p = 686 
0.0029 for ML-9 plaque counts and p < 0.0001 for ML-9 plaque size), followed by Tukey's post 687 





Fig. 2 Myosin IIA inhibition with (-)-blebbistatin and transfection of HeLa cells with MYH9 691 
siRNA reduces MLRM107 foci area. (A) - (C) HeLa cells were infected with S. flexneri 692 
MLRM107 in an infectious focus assay using a 12-well tray as described in the Methods. 693 
Infectious foci were imaged 24 h post gentamicin treatment. ≥ 15 infectious foci were imaged for 694 
each condition. (A) Images shown are overlay of an image taken with phase contrast and TxRed 695 
filter (10× magnification). The area of the infection focus i.e. area where mCherry was 696 
expressed, is outlined. Scale bar = 0.1 mm. (B) The total foci counts from one well or (C) mean 697 
foci area from one well were calculated. Data are represented as mean ± SEM of independent 698 
experiments (n = 3), analysed with one-way ANOVA (p < 0.0001 for foci counts and mean foci 699 
area), followed by Tukey's post hoc test (*p < 0.05, **p < 0.01). (D) - (G) HeLa cells were either 700 
mock transfected or transfected with control or MYH9 (myosin IIA) siRNA for 24 h, trypsinised 701 
and re-transfected for further 24 h. (D) HeLa cell extracts were probed with anti-Myosin IIA. 702 
GAPDH was used as a loading control. (E - G) Post transfection, HeLa cells were infected and 703 
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infectious foci were imaged as described in (A) - (C). (E) Images shown are overlay of an image 704 
taken with phase contrast and TxRed filter (10× magnification). The area of the infection focus 705 
i.e. area where mCherry was expressed, is outlined. Scale bar = 0.1 mm. (F) The total foci counts 706 
from one well or (G) mean foci area from one well were calculated. Data are represented as 707 
mean ± SEM of independent experiments (n = 3), analysed with one-way ANOVA (p > 0.05 for 708 
foci counts and p = 0.0003 mean foci area), followed by Tukey's post hoc test (***p < 0.001).  709 





Fig. 3 S. flexneri 2457T intracellular growth and protrusion formation in HeLa cells are not 713 
affected by of ML-7, ML-9, (+)-blebbistatin and (-)-blebbistatin. HeLa cells were infected 714 
with S. flexneri 2457T for 1 h in a 24-well tray. HeLa cells were washed thrice with D-PBS and 715 
incubated with MEM containing 40 µg mL
-1
 of gentamicin (t = 0) to exclude extracellular 716 
bacteria. Concurrently HeLa cells were treated with 30 μM ML-7, 50 μM ML-9, 50 μM (+)-717 
blebbistatin, 50 μM (-)-blebbistatin or DMSO. (A) To determine bacterial intracellular growth, 718 
two wells were prepared for each time point (t = 1, 2, 4 and 6 h) for each condition. At each 719 
interval, HeLa cells were washed, followed by lysis with 0.1% Triton X-100 to recover 720 
intracellular bacteria. Data are represented as mean from two-three independent experiments. (B 721 
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- C) At t = 1.5, HeLa cells were fixed to observe bacteria protrusions. (B) The percentage of 722 
infected cells with bacteria protrusion(s) were enumerated by counting >100 cells in each 723 
independent experiment. Data are represented as mean ± SEM of independent experiments (n = 724 
2), analysed with one-way ANOVA (p > 0.05). (C) Infected HeLa cells were imaged at 40× 725 
magnification. Scale bar = 10 μm. The arrows indicate protrusion formation. Insert shows 2× 726 







Fig. 4 Myosin IIA is localised to the S. flexneri 2457T F-actin tail and is not affected by 730 
MLCK and myosin II inhibitors. HeLa cells were infected with S. flexneri 2457T in an 731 
invasion assay as described in the Methods. Bacteria and HeLa nuclei were stained with DAPI 732 
(blue), F-actin was stained with FITC-phalloidin (green) and myosin IIA was stained with anti-733 
myosin IIA and Alexa Fluor 594-conjugated secondary antibody (red). Images were taken at 734 
100× magnification. Scale bar = 10 μm. HeLa cells were treated with DMSO, ML-7, ML-9, (+)-735 
blebbistatin, (-)-blebbistatin or were transfected with MYH9 siRNA and were infected with S. 736 
flexneri 2457T; (A) Untreated; (B) 1% DMSO; (C) 30 μM ML-7; (D) 50 μM ML-9; (E) 50 μM 737 
(+)-blebbistatin; (F) 50 μM (-)-blebbistatin; (G) MYH9 siRNA-transfected HeLa cells. 738 
Arrowheads indicate myosin IIA localisation at F-actin comet tails. Insert shows 1.5× 739 
enlargement of the indicated region. The experiment was repeated twice and representative 740 







Fig. 5 Myosin IIA protein levels are significantly reduced when infected with R-LPS and 744 
∆icsA S. flexneri strains. HeLa cells were infected with S. flexneri strains; (A) 2457T; (B) 745 
RMA723 (∆rmlD - R-LPS); (C) RMA2041 (∆icsA); (D) RMA2043 (∆icsA ∆rmlD); in an 746 
invasion assay as described in the Methods. Bacteria and HeLa nuclei were stained with DAPI 747 
(blue), F-actin was stained with FITC-phalloidin (green) and myosin IIA was stained with anti-748 
myosin IIA and Alexa Fluor 594-conjugated secondary antibody (red). Images were taken at 40× 749 
magnification. Scale bar = 20 μm. Infected HeLa cells are outlined. Infected HeLa cells with 750 
reduced myosin IIA labelling are marked with ‡. (E) The % myosin IIA labelling intensity of 751 
infected HeLa cells were compared with uninfected HeLa cells (set at 100%) in each individual 752 
image. In instances where infected HeLa cells have marked reduction in myosin IIA 753 
immunofluorescence, the infected HeLa cells are grouped into a separate category marked as (Lo 754 
= low) of the respective strains. The mean % myosin IIA labelling intensity of infected HeLa 755 
cells were determined by measuring ≥ 100 infected HeLa cells in each independent experiment 756 
for each category. Data are represented as mean ± SEM of independent experiments (n = 2), 757 
analysed with one-way ANOVA (p < 0.0001), followed by Tukey's post hoc test (**p < 0.01, 758 
***p < 0.001). (F) The % infected HeLa cells with low myosin IIA immunofluorescence was 759 
determined from the IF images analysed. Data are represented as mean ± SEM of independent 760 
experiments (n = 2), analysed with one-way ANOVA (p < 0.0001), followed by Tukey's post hoc 761 
test (*p < 0.05). 762 
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Fig. 6 Myosin IIB protein levels are not affected when infected with R-LPS and ∆icsA S. 764 
flexneri strains. HeLa cells were infected with S. flexneri strains; (A) 2457T; (B) RMA723 765 
(∆rmlD - R-LPS); (C) RMA2041 (∆icsA); (D) RMA2043 (∆icsA ∆rmlD); in an invasion assay as 766 
described in the Methods. Bacteria and HeLa nuclei were stained with DAPI (blue), F-actin was 767 
stained with FITC-phalloidin (green) and myosin IIB was stained with anti-myosin IIB and 768 
Alexa Fluor 594-conjugated secondary antibody (red). Images were taken at 100× magnification. 769 
Scale bar = 10 μm. Arrowheads indicate myosin IIB localisation at the F-actin comet tails. Insert 770 
shows 2× enlargement of the indicated region. The experiment was repeated twice and 771 
representative images are shown. 772 
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